BridgeBio signals 3 launches in next 7 months with BBP-418 November 27 PDUFA and infigratinib February 4, 2027 PDUFA (NASDAQ:BBIO)
· seekingalpha.com
BridgeBio Q3 2026 earnings highlight Attruby growth, strong cash, and key FDA catalysts ahead.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...